MRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, July 6, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Investors who purchased Mirati securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mrtx.                      

Bronstein, Gewirtz & Grossman, LLC

The investigation concerns whether Mirati and certain of its officers and/or directors have violated federal securities laws.

If you are aware of any facts relating to this investigation, or purchased Mirati shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/mrtx.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mrtx-investor-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-mirati-therapeutics-inc-and-encourages-investors-to-contact-the-firm-301088612.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.